Results 91 to 100 of about 949,070 (290)

SPARC Drives Podocyte Mitochondrial Damage and Ferroptosis in Diabetic Kidney Disease Following Klotho Deficiency

open access: yesAdvanced Science, EarlyView.
Klotho deficiency promotes podocyte mitochondrial dysfunction and ferroptosis through activation of the PKCα/CUX1/SPARC/TGFβ‐RII axis. SPARC emerges as a key mediator linking Klotho loss to podocyte injury in DKD and other kidney injury models, suggesting broader implications for CKD progression.
Qing Yang   +11 more
wiley   +1 more source

Pharmacology of Proteasome inhibitors

open access: yes, 2020
A review on the pharmacology of proteasome inhibitors. It focuses on its pharmacokinetics and its pharmacodynamics, mechanism of action and its effect on the therapy of various cancers especially in multiple myeloma and solid tumors.általános ...
Omalu, Chinedu Stephen
core  

An Effector TaCRVP From Tuta Absoluta Oral Secretion Impairs H2O2‐Mediated Plant Defense by Targeting Tomato SlCAT2

open access: yesAdvanced Science, EarlyView.
The Tuta absoluta salivary effector TaCRVP subverts tomato immunity by hijacking host catalase SlCAT2. Through a sophisticated dual mechanism, TaCRVP simultaneously promotes SlCAT2 tetramerization for activation and blocks its SlAdBiL‐mediated degradation for stabilization.
Jianquan Yan   +9 more
wiley   +1 more source

Towards subunit specific proteasome inhibitors [PDF]

open access: yes, 2011
This Thesis aims at the development of novel subunit selective inhibitors of the proteasome. -Three vinyl sulfone analogues of three epoxyketone containing inhibitors described in literature are synthesised and characterised.
Linden, W.A. van der
core  

Structure-Driven Developments of 26S Proteasome Inhibitors

open access: yes, 2016
The 26S proteasome is a 2.5-MDa complex, and it operates at the executive end of the ubiquitin-proteasome pathway. It is a proven target for therapeutic agents for the treatment of some cancers and autoimmune diseases, and moreover, it has potential as a
Sledz, P., Baumeister, W.
core   +1 more source

Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.

open access: yesPLoS Pathogens, 2019
Therapeutics with novel modes of action and a low risk of generating resistance are urgently needed to combat drug-resistant Plasmodium falciparum malaria.
Barbara H Stokes   +9 more
doaj   +1 more source

Autophagy Orchestrates Anti‐Tumor Immunity to Enhance Chemosensitivity via the FBXW2/C/EBPβ/TIMP‐2 Axis in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
Chemotherapy leverages tumor‐cell autophagy to reshape the colorectal cancer immune microenvironment. Autophagy degrades FBXW2 to promote C/EBPβ‐mediated TIMP‐2 transcription and MMP‐9 suppression, driving intra‐tumoral CD8+ T‐cell infiltration. Targeting MMP‐2/9 or restoring TIMP‐2 overcomes chemo‐resistance in autophagy‐deficient tumors. ABSTRACT The
Bing Cheng   +12 more
wiley   +1 more source

HDAC3 inhibitors affect proteasome activity.

open access: yes, 2014
A–C: HDAC3 inhibitors inhibit proteasome activity. Three different HDAC3 inhibitors were added to HeLa cell cultures at the indicated concentrations. After 48 h of incubation, the proteasome activity of 5 µg total protein in a PBS lysate was measured ...
Takayoshi Suzuki (172609)   +3 more
core   +1 more source

Integrated O2 and H2 Gas Therapy via Microneedle‐Assisted Photocatalytic Water Splitting for Accelerating Diabetic Full‐Thickness Skin Wound Healing

open access: yesAdvanced Science, EarlyView.
A concept of integrated O2 and H2 gas therapy is achieved using a gas‐producing material. PMP nanoparticles, fabricated from platinum, MIL‐101(Fe)‐NH2, and phosphotungstic acid, are integrated into bilayer gelatin methacryloyl microneedles for transdermal delivery. These microneedles enable integrated O2 and H2 gas therapy and promote wound healing via
Zesheng Chen   +13 more
wiley   +1 more source

Different proteasome inhibitors affect VSV replication.

open access: yes, 2013
(A) Proteasome inhibitor 1 and Bortezomib decreased VSV replication. Titration of VSV from the medium of overnight infected HeLa cells. VSV infection (MOI = 1) for one hour was substituted by the regular medium with indicated concentration of proteasome ...
Nickolay Neznanov (377911)   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy